RIPK3
Reaktivität: Human
IHC, ELISA
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
ELISA. Western blot: 0.5 to 1 μg/mL. Immunohistochemistry on paraffin sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
PBS, 0.02 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Certain serine/threonine protein kinases, such as ASK1, RIP, DAP, and ZIP kinases, are mediators of apoptosis. Receptor interacting proteins including RIP and RIP2/RICK mediate apoptosis induced by TNFR1 and Fas, two prototype members in the death receptor family. A novel member in the RIP kinase family was recently identified and designated RIP3 (1-3). RIP3 contains N-terminal kinase domain but, unlike RIP or RIP2, lacks the C-terminal death or CARD domain. RIP3 binds to RIP and TNFR1, mediates TNFR1 induced apoptosis, and attenuates RIP and TNFR1 induced NF-kB activation. Overexpression of RIP3 induces apoptosis and NF-kappaB activation. The messenger RNA of RIP3 is expressed in a subset of adult tissues (2,3).Synonyms: RIP-3, RIP-like protein kinase 3, Receptor-interacting protein 3, Receptor-interacting serine/threonine-protein kinase 3